Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.83
ARNA's Cash to Debt is ranked lower than
72% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. ARNA: 1.83 )
Ranked among companies with meaningful Cash to Debt only.
ARNA' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 5.06 Max: 11204.39
Current: 1.83
0.46
11204.39
Equity to Asset 0.06
ARNA's Equity to Asset is ranked lower than
90% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARNA: 0.06 )
Ranked among companies with meaningful Equity to Asset only.
ARNA' s Equity to Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.52 Max: 0.98
Current: 0.06
0.06
0.98
F-Score: 1
Z-Score: -8.86
M-Score: -3.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -275.58
ARNA's Operating margin (%) is ranked lower than
62% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. ARNA: -275.58 )
Ranked among companies with meaningful Operating margin (%) only.
ARNA' s Operating margin (%) Range Over the Past 10 Years
Min: -2405.23  Med: -443.1 Max: -28.18
Current: -275.58
-2405.23
-28.18
Net-margin (%) -291.35
ARNA's Net-margin (%) is ranked lower than
64% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. ARNA: -291.35 )
Ranked among companies with meaningful Net-margin (%) only.
ARNA' s Net-margin (%) Range Over the Past 10 Years
Min: -2421.99  Med: -525.21 Max: -23.88
Current: -291.35
-2421.99
-23.88
ROE (%) -179.47
ARNA's ROE (%) is ranked lower than
91% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ARNA: -179.47 )
Ranked among companies with meaningful ROE (%) only.
ARNA' s ROE (%) Range Over the Past 10 Years
Min: -246.16  Med: -96.22 Max: -20.4
Current: -179.47
-246.16
-20.4
ROA (%) -39.66
ARNA's ROA (%) is ranked lower than
61% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. ARNA: -39.66 )
Ranked among companies with meaningful ROA (%) only.
ARNA' s ROA (%) Range Over the Past 10 Years
Min: -65.19  Med: -37.22 Max: -6.47
Current: -39.66
-65.19
-6.47
ROC (Joel Greenblatt) (%) -134.72
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. ARNA: -134.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARNA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -279.74  Med: -114.62 Max: -16.16
Current: -134.72
-279.74
-16.16
Revenue Growth (3Y)(%) 22.70
ARNA's Revenue Growth (3Y)(%) is ranked higher than
76% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ARNA: 22.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARNA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.2 Max: 34.9
Current: 22.7
0
34.9
EBITDA Growth (3Y)(%) -26.80
ARNA's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. ARNA: -26.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARNA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -70.8  Med: -16.75 Max: 74.3
Current: -26.8
-70.8
74.3
EPS Growth (3Y)(%) -29.50
ARNA's EPS Growth (3Y)(%) is ranked lower than
79% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARNA: -29.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARNA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.2  Med: -18.05 Max: 105.9
Current: -29.5
-57.2
105.9
» ARNA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ARNA Guru Trades in Q3 2015

Jim Simons 2,102,200 sh (+26.12%)
Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
» More
Q4 2015

ARNA Guru Trades in Q4 2015

Paul Tudor Jones 114,543 sh (New)
Jim Simons 3,129,200 sh (+48.85%)
Ken Fisher 11,100 sh (+0.91%)
Murray Stahl 45,000 sh (unchged)
» More
Q1 2016

ARNA Guru Trades in Q1 2016

Jim Simons 4,423,855 sh (+41.37%)
Murray Stahl 45,000 sh (unchged)
Ken Fisher Sold Out
Paul Tudor Jones 28,118 sh (-75.45%)
» More
Q2 2016

ARNA Guru Trades in Q2 2016

Jim Simons 5,601,355 sh (+26.62%)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones 26,203 sh (-6.81%)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RVNC, NAS:ADXS, NAS:SRNE, NAS:CTMX, OTCPK:TYMI, NAS:TLGT, NAS:MNKD, NAS:VSAR, NAS:NERV, NAS:ARWR, NAS:OMER, NAS:XBIT, NAS:TRVN, NAS:ENTA, OTCPK:ZLDPF, NAS:RETA, NAS:GERN, NAS:MCRB, NAS:NDRM, NAS:CLDX » details
Traded in other countries:RN3.Germany,
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Arena Pharmaceuticals Inc was incorporated in the state of Delaware in April 14, 1997, and commenced operations in July 1997. The Company is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ, its internally discovered drug for chronic weight management in adults who are overweight with a comorbidity or obese, is its first and only drug approved for marketing by any regulatory agency. In June 2012, the U.S. Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company is engaged in commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. Its programs include: BELVIQ, for chronic weight management; APD811, an orally available agonist of the prostacyclin (IP) receptor, is an internally discovered investigational drug candidate intended for the treatment of Pulmonary Arterial Hypertension; Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases; APD334, an orally available agonist of the S1P1 receptor, is an internally discovered investigational drug candidate intended for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis; APD371, an orally available agonist of the cannabinoid 2 receptor, is an internally discovered investigational drug candidate intended for the treatment of pain; GPR119, represents pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, granted Eisai Inc., and Eisai Inc.'s parent company, Eisai Co. Ltd. exclusive rights to commercialize BELVIQ in the United States. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's research and development programs involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, the Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.

Ratios

vs
industry
vs
history
P/B 29.11
ARNA's P/B is ranked lower than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ARNA: 29.11 )
Ranked among companies with meaningful P/B only.
ARNA' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 5.48 Max: 35.54
Current: 29.11
1.23
35.54
P/S 10.87
ARNA's P/S is ranked higher than
51% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. ARNA: 10.87 )
Ranked among companies with meaningful P/S only.
ARNA' s P/S Range Over the Past 10 Years
Min: 7.85  Med: 22.98 Max: 84.8
Current: 10.87
7.85
84.8
EV-to-EBIT -3.45
ARNA's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. ARNA: -3.45 )
Ranked among companies with meaningful EV-to-EBIT only.
ARNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -224.2  Med: -3.8 Max: -0.3
Current: -3.45
-224.2
-0.3
EV-to-EBITDA -3.83
ARNA's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. ARNA: -3.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -305.9  Med: -4.2 Max: 829.5
Current: -3.83
-305.9
829.5
Current Ratio 2.56
ARNA's Current Ratio is ranked lower than
68% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. ARNA: 2.56 )
Ranked among companies with meaningful Current Ratio only.
ARNA' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 7.04 Max: 91.72
Current: 2.56
1.68
91.72
Quick Ratio 2.39
ARNA's Quick Ratio is ranked lower than
66% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ARNA: 2.39 )
Ranked among companies with meaningful Quick Ratio only.
ARNA' s Quick Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.9 Max: 91.72
Current: 2.39
1.68
91.72
Days Inventory 283.84
ARNA's Days Inventory is ranked lower than
82% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. ARNA: 283.84 )
Ranked among companies with meaningful Days Inventory only.
ARNA' s Days Inventory Range Over the Past 10 Years
Min: 301.17  Med: 554.86 Max: 555.68
Current: 283.84
301.17
555.68
Days Sales Outstanding 33.66
ARNA's Days Sales Outstanding is ranked higher than
73% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. ARNA: 33.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.7  Med: 42.1 Max: 76.88
Current: 33.66
3.7
76.88
Days Payable 119.51
ARNA's Days Payable is ranked higher than
72% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. ARNA: 119.51 )
Ranked among companies with meaningful Days Payable only.
ARNA' s Days Payable Range Over the Past 10 Years
Min: 106.48  Med: 176.78 Max: 386.18
Current: 119.51
106.48
386.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.70
ARNA's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ARNA: -14.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -205.6  Med: -23.55 Max: 1.2
Current: -14.7
-205.6
1.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 67.92
ARNA's Price/Tangible Book is ranked lower than
98% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ARNA: 67.92 )
Ranked among companies with meaningful Price/Tangible Book only.
ARNA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.62  Med: 3.08 Max: 71.25
Current: 67.92
0.62
71.25
Price/Median PS Value 0.48
ARNA's Price/Median PS Value is ranked higher than
82% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARNA: 0.48 )
Ranked among companies with meaningful Price/Median PS Value only.
ARNA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 0.72 Max: 2.68
Current: 0.48
0.34
2.68
Earnings Yield (Greenblatt) (%) -29.00
ARNA's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ARNA: -29.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARNA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -43.98  Med: 610.95 Max: 30966.3
Current: -29
-43.98
30966.3

More Statistics

Revenue (TTM) (Mil) $36.25
EPS (TTM) $ -0.44
Beta1.52
Short Percentage of Float5.84%
52-Week Range $1.30 - 2.99
Shares Outstanding (Mil)243.26

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 33 80
EPS ($) -0.25 0.02
EPS w/o NRI ($) -0.25 0.02
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 25 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016 Aug 23 2016
ARENA PHARMACEUTICALS INC Financials Aug 18 2016
Biotech Industry on the Upswing after Rocky Start to 2016 Aug 17 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 15 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer Aug 15 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer Aug 15 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016 Aug 11 2016
Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y Aug 09 2016
ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss? Aug 08 2016
Arena Pharmaceuticals reports 2Q loss Aug 08 2016
Arena Pharmaceuticals reports 2Q loss Aug 08 2016
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 08 2016
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
What to Expect in Arena Pharmaceuticals Earnings? Aug 08 2016
Q2 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close Aug 08 2016
Small Cell as a Service connects crowds at Wasps' Ricoh Arena Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)